Valerio Therapeutics Announces Binding Offer for the Proposed Acquisition of Etherna Immunotherapies, Creating a Global Leader in Targeted RNA Medicines
The proposed acquisition represents a major step in Valerio's strategy to become a leading developer of next-generation targeted RNA medicines targeting cells beyond the liver, addressing diseases with high unmet medical needs
The acquisition aims to create the only player combining active sdAb targeting and passive LNP delivery within a fully integrated RNA medicines platform, accelerating the development of therapeutics and supporting a growing proprietary pipeline
The news follows the recent appointment of seasoned biotech leader Gilles Besin as Chief Executive Officer to lead Valerio's next phase of innovation in precision targeted therapeutics, bringing deep expertise in RNA medicines, targeted delivery and in vivo cell therapy
Supported by leading life sciences investors, with key Etherna shareholders becoming Valerio shareholders as part of the transaction, reflecting confidence in the strategic vision and value creation potential of the combined entities
